Let The Scapegoating Begin: Senate Price Hearing Hits Safe Themes For Innovators
This article was originally published in RPM Report
The political response to the outrage over brand name drug pricing continues to play surprisingly well for most innovator companies. The first hearing focused on defining a group of “bad actors” separate and apart from innovators. Generic companies fared surprisingly poorly as well.